0001178913-20-001327.txt : 20200506 0001178913-20-001327.hdr.sgml : 20200506 20200506070016 ACCESSION NUMBER: 0001178913-20-001327 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200506 FILED AS OF DATE: 20200506 DATE AS OF CHANGE: 20200506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evogene Ltd. CENTRAL INDEX KEY: 0001574565 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE CHEMICALS [2870] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36187 FILM NUMBER: 20851075 BUSINESS ADDRESS: STREET 1: 13 GAD FEINSTEIN STREET STREET 2: PARK REHOVOT P.O.B 2100 CITY: REHOVOT STATE: L3 ZIP: 76121 BUSINESS PHONE: 97289311900 MAIL ADDRESS: STREET 1: 13 GAD FEINSTEIN STREET STREET 2: PARK REHOVOT P.O.B 2100 CITY: REHOVOT STATE: L3 ZIP: 76121 6-K 1 zk2024362.htm 6-K

UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of May 2020
 
Commission File Number: 001-36187

EVOGENE LTD.
  (Translation of Registrant’s Name into English)
 
13 Gad Feinstein Street
Park Rehovot P.O.B 2100
Rehovot 7612002 Israel
(Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F ☒ Form 40-F ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 

CONTENTS
 
Evogene Ltd., or the Company, reports changes in its management:
 
Mr. Nir Nimrodi has been appointed as Special Advisor to the board. Mr. Nimrodi brings diverse international experience leading global businesses in the biotech and life science industries. Mr. Nimrodi previously was employed at Intrexon Corporation from 2014 to 2019, where he most recently held the position of Chief Business Officer. His background includes strategic planning, business development, full P&L management, M&A, operations, fund raising and investor relations. Mr. Nimrodi currently serves as the Chairman and CEO of Accellix, and has previously held positions with Life Technologies, Proneuron Biotechnologies, Mindsense Biosystems and Teva Pharmaceuticals. Mr. Nimrodi is located in the greater San Diego area, USA.
 
Mr. Gadi Ben Nissim has been appointed EVP Corporate Development.  Mr. Ben Nissim brings over 20 years of versatile international experience within the pharmaceutical industry in both generics and specialty brands, across various geographies. Mr. Ben Nissim previously held various senior leadership roles with Teva Pharmaceuticals as well as with Mayne Pharma, with a focus on leading commercial business units, business development, strategic and financial planning, new markets development, and post-merger integrations. Mr. Ben Nissim is located in Israel.
 
2
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 



Date: May 6, 2020
  
EVOGENE  LTD.
(Registrant)

By: /s/ Dorit Kreiner
——————————————
Dorit Kreiner
Chief Financial Officer

3